Exclusive Summary

• Manufactured in a US-FDA approved GMP facility with USP/EP compliant API, ensuring top-tier global compliance for seamless entry into regulated markets and fast-tracked registration in emerging markets.
• As a complex injectable (liposomal formulation) with exceedingly high technical barriers, it faces minimal global generic competition, offering distributors a substantial first-mover or quasi-monopoly advantage.
• Highly recommended by NCCN/ESMO guidelines as the standard of care for metastatic pancreatic cancer, directly addressing a massive unmet clinical need for over 500k new patients annually global wide.
• Offers a drastic cost advantage compared to the exorbitantly priced innovator drug (Onivyde), ensuring strong competitiveness in national tenders and highly lucrative margins for localization partners.